2 hours ago · United States
US regulator investigates tumour risk in children given Novartis gene therapy
What's happening
SignalsMonitor is following this as a general story. South China Morning Post Asia is the outlet attached so far. The reports are tied to United States. The first report grouped here was at 7 Nov 2026, 03:35 UTC. The headline in use is “US regulator investigates tumour risk in children given Novartis gene therapy”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
The US Food and Drug Administration said on Friday it was investigating a risk of neoplasia, or tumour formation including malignancy, associated with Novartis’ gene therapy Zolgensma. The Swiss drug maker earlier in the day disclosed two cases in which tumours in children showed evidence of being linked to its…
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by South China Morning Post Asia
US regulator investigates tumour risk in children given Novartis gene therapy
Reported by 1 outlet
- South China Morning Post
- South China Morning PostUS regulator investigates tumour risk in children given Novartis gene therapy